Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab vs Bevacizumab for Conversion Therapy in Right-sided Colon Cancer
NCT04525326Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Oct 2020
- Primary completion
- Oct 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of cetuximab, bevacizumab in colorectal cancer (CRC), liver metastasis, sponsored by Fudan University. Status: unknown.
02
Drugs
cetuximabbevacizumab
03
Conditions
colorectal cancer (CRC)liver metastasis
Beyond the preview
Go deeper on NCT04525326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04525326.